Clinical Trial Update: A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update for TAR-200 in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy and unfi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urinary Bladder Neoplasms | Phase 1 | Status: COMPLETED